166 related articles for article (PubMed ID: 25188607)
1. Antitumor Efficacy of Docetaxel-loaded Nanocarrier against Esophageal Cancer Cell Bearing Mice Model.
Huang ZJ; Yang N; Xu TW; Lin JQ
Drug Res (Stuttg); 2015 Aug; 65(8):403-9. PubMed ID: 25188607
[TBL] [Abstract][Full Text] [Related]
2. Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Miyanaga S; Ninomiya I; Tsukada T; Okamoto K; Harada S; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2016 Feb; 48(2):517-24. PubMed ID: 26676807
[TBL] [Abstract][Full Text] [Related]
3. A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
Su X; Gao C; Shi F; Feng X; Liu L; Qu D; Wang C
Drug Deliv; 2017 Nov; 24(1):10-19. PubMed ID: 28155336
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of in vitro efficacy of docetaxel-loaded calcium carbonate aragonite nanoparticles (DTX-CaCO
Hammadi NI; Abba Y; Hezmee MNM; Razak ISA; Kura AU; Zakaria ZAB
In Vitro Cell Dev Biol Anim; 2017 Dec; 53(10):896-907. PubMed ID: 28916966
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
6. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Hwang HY; Kim IS; Kwon IC; Kim YH
J Control Release; 2008 May; 128(1):23-31. PubMed ID: 18374444
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (L
Su CY; Liu JJ; Ho YS; Huang YY; Chang VH; Liu DZ; Chen LC; Ho HO; Sheu MT
Eur J Pharm Biopharm; 2018 Feb; 123():9-19. PubMed ID: 29154834
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and antitumor evaluation of CMCS-DTX conjugates as novel delivery platform for docetaxel.
Liu F; Feng L; Zhang L; Zhang X; Zhang N
Int J Pharm; 2013 Jul; 451(1-2):41-9. PubMed ID: 23608199
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded trimethyl chitosan-based polymeric nanoparticle for the effective treatment of gastroenteric tumors.
Song RF; Li XJ; Cheng XL; Fu AR; Wang YH; Feng YJ; Xiong Y
Oncol Rep; 2014 Oct; 32(4):1481-8. PubMed ID: 25051142
[TBL] [Abstract][Full Text] [Related]
10. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
Xu WW; Liu DY; Cao YC; Wang XY
Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer.
Conte C; Ungaro F; Maglio G; Tirino P; Siracusano G; Sciortino MT; Leone N; Palma G; Barbieri A; Arra C; Mazzaglia A; Quaglia F
J Control Release; 2013 Apr; 167(1):40-52. PubMed ID: 23298613
[TBL] [Abstract][Full Text] [Related]
12. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
13. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
Doddapaneni R; Patel K; Chowdhury N; Singh M
Exp Cell Res; 2016 Aug; 346(1):65-73. PubMed ID: 27177833
[TBL] [Abstract][Full Text] [Related]
14. Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel.
Li B; Zhang XX; Huang HY; Chen LQ; Cui JH; Liu Y; Jin H; Lee BJ; Cao QR
Int J Pharm; 2018 May; 543(1-2):8-20. PubMed ID: 29535039
[TBL] [Abstract][Full Text] [Related]
15. Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma.
Du N; Song LP; Li XS; Wang L; Wan L; Ma HY; Zhao H
J Nanobiotechnology; 2015 Feb; 13():17. PubMed ID: 25889600
[TBL] [Abstract][Full Text] [Related]
16. Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer.
Liang Z; Yang N; Jiang Y; Hou C; Zheng J; Shi J; Zhang R; Li D; Liu Y; Zuo P
Int J Pharm; 2015 Oct; 494(1):337-45. PubMed ID: 26299762
[TBL] [Abstract][Full Text] [Related]
17. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Ostacolo L; Marra M; Ungaro F; Zappavigna S; Maglio G; Quaglia F; Abbruzzese A; Caraglia M
J Control Release; 2010 Dec; 148(2):255-63. PubMed ID: 20816710
[TBL] [Abstract][Full Text] [Related]
18. PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy.
Wang Y; Chen L; Tan L; Zhao Q; Luo F; Wei Y; Qian Z
Biomaterials; 2014 Aug; 35(25):6972-85. PubMed ID: 24836952
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors.
Su CY; Chen M; Chen LC; Ho YS; Ho HO; Lin SY; Chuang KH; Sheu MT
Drug Deliv; 2018 Nov; 25(1):1066-1079. PubMed ID: 29718725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
